Navigation Links
Biomarker Uncovered by Roswell Park Team Identifies NET Patients Likely to Have Blood Side Effects from PRRT
Date:6/8/2021

New work from a team at Roswell Park Comprehensive Cancer Center will help guide the care of patients with neuroendocrine tumors, or NETs. In a poster presentation at the American Society of Clinical Oncology (ASCO) virtual Annual Meeting 2021, Abhay Singh, MD, MPH, and colleagues outline their discovery of a potential biomarker to predict which patients are likely to experience blood toxicity side effects from a new targeted radiation treatment, peptide receptor radionuclide therapy (PRRT).

While PRRT has been shown to be beneficial for patients with neuroendocrine tumors, it sometimes causes hematologic side effects that can be permanent. The study, Mutant PPM1D and TP53 populate the hematopoietic compartment after peptide receptor radionuclide therapy (PRRT) exposure (abstract 10605), demonstrates that clonal expansion of cells harboring certain genetic mutations contributes to blood toxicities following this treatment.

“With the application of highly sensitive and state-of-the-art sequencing technologies, our group has identified — for the first time — a high incidence of premalignant hematopoiesis or clonal hematopoiesis in neuroendocrine tumor patients,” reports Dr. Singh, a Hematology-Oncology Fellow at Roswell Park.

The researchers analyzed patients’ blood samples before and after PRRT, looking for clonal mutations that may help characterize the selective pressures this therapy puts on stem cells. They used a targeted 100-gene molecular panel, and set a variant allele frequency cutoff of 1 percent to classify clonal hematopoiesis.

“Fifty-four percent of patients were noted to have clonal hematopoiesis in our study,” he continues. “We have reported the presence of putative therapy-related myeloid neoplasm driver mutations such as those involving DNA-damage response genes, for example, TP53 and PPM1D, prior to peptide receptor radionuclide therapy exposure.”

Using genomic sequencing to track these mutations, the team uncovered the presence of expanding all elic fractions of DDR clones following PRRT.

“These large shifts in allelic frequencies are highly significant, as they were associated with emergence and persistence of clinically significant cytopenias or PRRT-associated hematological toxicity,” notes study co-author Eunice Wang, MD, Chief of Leukemia at Roswell Park.

“We believe that the detection of clonal hematopoiesis mutations in DDR genes offers the first potential predictive biomarker to assess risk of subsequent hematological toxicity to peptide receptor radionuclide therapy in patients receiving this novel therapy,” says Dr. Wang, who is also Professor of Oncology and Medical Director of Infusion Services.

“Screening and longitudinal monitoring of clonal hematopoiesis may serve as a key risk-mitigation strategy for patients with neuroendocrine tumors receiving peptide receptor radionuclide therapy.”

Another important consideration before prescribing this novel therapy is that PRRT’s selective pressures have varying effects on different mutations. The researchers note that a larger study with longer patient follow-up is needed to better understand the biology of therapy related-myeloid neoplasms and the link between therapy related-clonal hematopoiesis and cytopenias.

###
This release is also available at: https://www.roswellpark.org/newsroom/202106-biomarker-uncovered-roswell-park-team-identifies-net-patients-likely-have-blood

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Read the full story at https://www.prweb.com/releases/biomarker_uncovered_by_roswell_park_team_identifies_net_patients_likely_to_have_blood_side_effects_from_prrt/prweb17990888.htm.


'/>"/>
Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved


Related medicine technology :

1. ValenzaBio Selects Ready by ArcheMedX to Expedite Biomarker Study
2. Demiurge Technologies AG: Clinically Validated Pathology-based AI Prediction of ACE2 Expression as A Predictive Biomarker of COVID-19 Mortality Rate
3. Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial
4. Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project, Upcoming Webinar Hosted by Xtalks
5. Dynamical Biomarkers Group Reaches Final Of Qualcomm Tricorder XPRIZE Challenge
6. Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes
7. Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023 (Focus on Biomarker Test Type, Application & Market Trends)
8. Breast Cancer Index(SM) (BCI) Included in Updated Guidelines for Use of Clinical Biomarkers in Breast Cancer
9. NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising biomarker data
10. Global Cardiac Biomarker Market Analysis 2016 - Forecast to 2022 - By Biomarkers Type, Product, Application & Type of Testing - Research and Markets
11. Cancer Biomarkers Market to Reach $15,737 Million, Globally, by 2022 - Allied Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):